Literature DB >> 19744475

Modulatory effects of probenecid on the nitroglycerin-induced changes in the rat caudal trigeminal nucleus.

Eniko Vamos1, Arpad Pardutz, Annamaria Fejes, Janos Tajti, Jozsef Toldi, Laszlo Vecsei.   

Abstract

Four hours after systemic administration of the nitric oxide donor nitroglycerin (10 mg/kg bodyweight, s.c.), the neurons of the rat caudal trigeminal nucleus are activated, the area covered by calcitonin gene-related peptide (CGRP)-immunoreactive fibres is decreased and the neuronal nitric oxide synthase (nNOS)- and the calmodulin-dependent protein kinase II alpha (CamKIIalpha)-immunopositive neurons in the same area are increased. Probenecid is a non-selective inhibitor of multidrug-resistance associated proteins and organic anion transporters thus it can modulate the transport functions in the central nervous system influencing nociception. Accordingly, the aim of the present experiments was to examine the effects of probenecid administration on the nitroglycerin-induced expressions of nNOS, CamKIIalpha and CGRP in the rat caudal trigeminal nucleus. Probenecid (200 mg/kg bodyweight, i.p.) pretreatment proved to mitigate the nitroglycerin-induced changes in expression in the rat caudal trigeminal nucleus. The data suggest that the changes caused by nitroglycerin in the expressions of CGRP, nNOS and CamKIIalpha can be influenced by probenecid modulating the inflammatory functions in the nervous system. These data may be of relevance for the pathogenesis of migraine headache.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19744475     DOI: 10.1016/j.ejphar.2009.08.034

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Inhibition of blood-brain barrier efflux transporters promotes seizure in pregnant rats: Role of circulating factors.

Authors:  Abbie C Johnson; Erica S Hammer; Sophie Sakkaki; Sarah M Tremble; Gregory L Holmes; Marilyn J Cipolla
Journal:  Brain Behav Immun       Date:  2017-07-21       Impact factor: 7.217

Review 2.  Migraine is a neuronal disease.

Authors:  J Tajti; A Párdutz; E Vámos; B Tuka; A Kuris; Zs Bohár; A Fejes; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2010-12-15       Impact factor: 3.575

3.  Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation.

Authors:  Sheryl E Koch; Xiaoqian Gao; Lauren Haar; Min Jiang; Valerie M Lasko; Nathan Robbins; Wenfeng Cai; Cole Brokamp; Priyanka Varma; Michael Tranter; Yong Liu; Xiaoping Ren; John N Lorenz; Hong-Sheng Wang; W Keith Jones; Jack Rubinstein
Journal:  J Mol Cell Cardiol       Date:  2012-04-27       Impact factor: 5.000

Review 4.  Involvement of gap junction channels in the pathophysiology of migraine with aura.

Authors:  Denis Sarrouilhe; Catherine Dejean; Marc Mesnil
Journal:  Front Physiol       Date:  2014-02-25       Impact factor: 4.566

Review 5.  Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines.

Authors:  Dénes Zádori; Péter Klivényi; Imola Plangár; József Toldi; László Vécsei
Journal:  J Cell Mol Med       Date:  2011-04       Impact factor: 5.310

Review 6.  Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine.

Authors:  Gábor Nagy-Grócz; Ferenc Zádor; Szabolcs Dvorácskó; Zsuzsanna Bohár; Sándor Benyhe; Csaba Tömböly; Árpád Párdutz; László Vécsei
Journal:  Int J Mol Sci       Date:  2017-07-30       Impact factor: 5.923

7.  Botulinum toxin type a therapy in migraine: preclinical and clinical trials.

Authors:  Yu-Feng Shao; Yi Zhang; Peng Zhao; Wen-Jun Yan; Xiang-Pan Kong; Lin-Lan Fan; Yi-Ping Hou
Journal:  Iran Red Crescent Med J       Date:  2013-10-05       Impact factor: 0.611

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.